CME credits: 0.25 
Valid until: 15-01-2022 
Claim your CME credit at <a href="https://reachmd.com/programs/cme/new-horizons-alzheimers-disease/12108/">https://reachmd.com/programs/cme/new-horizons-alzheimers-disease/12108/</a> 


 Once an Alzheimer’s disease diagnosis is made, the next challenge is treatment. Dr. Alizera Atri and Dr. Marwan Sabbagh discuss the current standard of care, the clinical pipeline for Alzheimer’s disease, and the role of amyloid-beta-targeted antibodies.

CME credits: 0.25 Valid until: 15-01-2022 Claim your CME credit at https://reachmd.com/programs/cme/new-horizons-alzheimers-disease/12108/ Once an Alzheimer’s disease diagnosis is made, the next challenge is treatment. Dr. Alizera Atri and Dr. Marwan Sabbagh discuss the current standard of care, the clinical pipeline for Alzheimer’s disease, and the role of amyloid-beta-targeted antibodies.

CME credits: 0.25 
Valid until: 15-01-2022 
Claim your CME credit at <a href="https://reachmd.com/programs/cme/new-horizons-alzheimers-disease/12108/" rel="noopener noreferrer">https://reachmd.com/programs/cme/new-horizons-alzheimers-disease/12108/</a> 


 Once an Alzheimer’s disease diagnosis is made, the next challenge is treatment. Dr. Alizera Atri and Dr. Marwan Sabbagh discuss the current standard of care, the clinical pipeline for Alzheimer’s disease, and the role of amyloid-beta-targeted antibodies.

New Horizons in Alzheimer’s Disease

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.

Share New Horizons in Alzheimer’s Disease

Sign up to save your podcasts

New Horizons in Alzheimer’s Disease

New Horizons in Alzheimer’s Disease